AMLX (Amylyx Pharmaceuticals) Other Current Liabilities: $3.20 Mil (As of Mar. 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $18.28
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Other Current Liabilities?

Amylyx Pharmaceuticals AMLX +1.81% 33 Other Current Liabilities is $3.20 Mil as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Amylyx Pharmaceuticals's other current liabilities for the quarter that ended in Mar. 2026 was $3.20 Mil.

Amylyx Pharmaceuticals's quarterly other current liabilities increased from Sep. 2025 ($9.81 Mil) to Dec. 2025 ($10.06 Mil) but then declined from Dec. 2025 ($10.06 Mil) to Mar. 2026 ($3.20 Mil).

Amylyx Pharmaceuticals's annual other current liabilities declined from Dec. 2023 ($16.79 Mil) to Dec. 2024 ($9.99 Mil) but then increased from Dec. 2024 ($9.99 Mil) to Dec. 2025 ($10.06 Mil).

Amylyx Pharmaceuticals Other Current Liabilities Related Terms

Amylyx Pharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals Other Current Liabilities Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 4.28 15.23 16.79 9.99 10.06

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.37 6.95 9.81 10.06 3.20
AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.20 Mil mean?
Amylyx Pharmaceuticals (AMLX) has a Other Current Liabilities of $3.20 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amylyx Pharmaceuticals.
Is Amylyx Pharmaceuticals' Other Current Liabilities too high?
Amylyx Pharmaceuticals' current Other Current Liabilities is $3.20 Mil. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Other Current Liabilities compare to ANIP and TRLV?
Amylyx Pharmaceuticals' Other Current Liabilities of $3.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amylyx Pharmaceuticals. Amylyx Pharmaceuticals's current Other Current Liabilities is $3.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Other Current Liabilities of $3.20 Mil. The current Other Current Liabilities is $3.20 Mil. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Other Current Liabilities is $3.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.28
Price